Outcome measurement in functional neurological disorder: a systematic review and recommendations.,Journal of Neurology, Neurosurgery, and Psychiatry

当前位置： X-MOL 学术 › J. Neurol. Neurosurg. Psychiatry › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Outcome measurement in functional neurological disorder: a systematic review and recommendations.
Journal of Neurology, Neurosurgery, and Psychiatry ( IF 11.0 ) Pub Date : 2020-02-28 , DOI: 10.1136/jnnp-2019-322180
Susannah Pick ₁ , David G Anderson ₂ , Ali A Asadi-Pooya _{3,

4} , Selma Aybek ₅ , Gaston Baslet ₆ , Bastiaan R Bloem ₇ , Abigail Bradley-Westguard , Richard J Brown ₈ , Alan J Carson ₉ , Trudie Chalder ₁ , Maria Damianova ₂ , Anthony S David ₁₀ , Mark J Edwards ₁₁ , Steven A Epstein ₁₂ , Alberto J Espay ₁₃ , Béatrice Garcin ₁₄ , Laura H Goldstein ₁ , Mark Hallett ₁₅ , Joseph Jankovic ₁₆ , Eileen M Joyce ₁₇ , Richard A Kanaan ₁₈ , Roxanne C Keynejad ₁ , Kasia Kozlowska ₁₉ , Kathrin LaFaver ₂₀ , W Curt LaFrance ₂₁ , Anthony E Lang ₂₂ , Alex Lehn ₂₃ , Sarah Lidstone ₂₂ , Carine W Maurer ₂₄ , Bridget Mildon ₂₅ , Francesca Morgante ₁₁ , Lorna Myers ₂₆ , Clare Nicholson ₂₇ , Glenn Nielsen ₁₁ , David L Perez ₂₈ , Stoyan Popkirov ₂₉ , Markus Reuber ₃₀ , Karen S Rommelfanger ₃₁ , Petra Schwingenshuh ₃₂ , Tereza Serranova ₃₃ , Paul Shotbolt ₁ , Glenn T Stebbins ₃₄ , Jon Stone ₉ , Marina Aj Tijssen ₃₅ , Michele Tinazzi ₃₆ , Timothy R Nicholson ₃₇

Affiliation

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Donald Gordon Medical Centre, University of the Witwatersrand, Johannesburg, South Africa.
Epilepsy Research Center, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of.
Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Department of Neurology, University Hospital Bern & University of Bern, Bern, Switzerland.
Department of Psychiatry, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Department of Neurology, Radboud University Nijmegen Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Netherlands.
School of Health Sciences, The University of Manchester, Manchester, UK.
Department of Clinical Neurosciences, School of Molecular and Clinical Medicine, Western General Hospital, University of Edinburgh, Edinburgh, UK.
Institute of Mental Health, Division of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom.
Neuroscience Research Centre, Institute of Molecular and Clinical Sciences, St George's University, London, UK.
Department of Psychiatry, Georgetown University, Washington, District of Columbia, USA.
Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.
Department of Neurology, Hopital Avicenne, Assistance Publique, Hôpitaux de Paris, Paris, Île-de-France, France.
Human Motor Control Section, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA.
Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
University College London Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
Department of Psychiatry, Austin Health, University of Melbourne, Melbourne, Victoria, Australia.
Discipline of Psychiatry and Child and Adolescent Health, The Children's Hospital at Westmead, Sydney Medical School, Sydney, New South Wales, Australia.
Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Departments of Psychiatry and Neurology, Rhode Island Hospital, Brown Medical School, Providence, RI, USA.
Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, University Health Network, Toronto, Ontario, Canada.
Mater Neurosciences Centre, Brisbane, Queensland, Australia.
Department of Neurology, Stony Brook University Renaissance School of Medicine, Stony Brook, New York, USA.
FND Hope International, Salmon, Idaho, USA.
Northeast Regional Epilepsy Group, New York, New York, USA.
Therapy Services, The National Hospital for Neurology and Neurosurgery, London, UK.
Departments of Neurology and Psychiatry, Therapy Services, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.
Academic Neurology Unit, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK.
Departments of Neurology and Psychiatry and Behavioral Sciences, Emory Centre for Ethics, Emory University School of Medicine, Atlanta, Georgia, USA.
Department of Neurology, Medical University of Graz, Graz, Austria.
Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, Prague, Czech Republic.
Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Department of Neuroscience, Biomedicine, and Movement, University of Verona, Verona, Italy.
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

OBJECTIVES We aimed to identify existing outcome measures for functional neurological disorder (FND), to inform the development of recommendations and to guide future research on FND outcomes. METHODS A systematic review was conducted to identify existing FND-specific outcome measures and the most common measurement domains and measures in previous treatment studies. Searches of Embase, MEDLINE and PsycINFO were conducted between January 1965 and June 2019. The findings were discussed during two international meetings of the FND-Core Outcome Measures group. RESULTS Five FND-specific measures were identified-three clinician-rated and two patient-rated-but their measurement properties have not been rigorously evaluated. No single measure was identified for use across the range of FND symptoms in adults. Across randomised controlled trials (k=40) and observational treatment studies (k=40), outcome measures most often assessed core FND symptom change. Other domains measured commonly were additional physical and psychological symptoms, life impact (ie, quality of life, disability and general functioning) and health economics/cost-utility (eg, healthcare resource use and quality-adjusted life years). CONCLUSIONS There are few well-validated FND-specific outcome measures. Thus, at present, we recommend that existing outcome measures, known to be reliable, valid and responsive in FND or closely related populations, are used to capture key outcome domains. Increased consistency in outcome measurement will facilitate comparison of treatment effects across FND symptom types and treatment modalities. Future work needs to more rigorously validate outcome measures used in this population.

中文翻译：

功能性神经系统疾病的结果测量：系统评价和建议。

目的我们旨在确定功能性神经疾病（FND）的现有结果指标，为建议的制定提供信息并指导有关FND结果的未来研究。方法进行了系统的审查，以确定现有的FND特定的结局指标，以及先前治疗研究中最常见的指标领域和指标。在1965年1月至2019年6月之间对Embase，MEDLINE和PsycINFO进行了搜索。在FND核心成果度量小组的两次国际会议上讨论了这些发现。结果确定了五种针对FND的特定措施-三名临床医生评级和两名患者评级-但尚未对其评估特性进行严格评估。在成人的FND症状范围内，未发现可使用的任何单一措施。在随机对照试验（k = 40）和观察性治疗研究（k = 40）中，结局指标最常评估核心FND症状变化。通常测量的其他领域是其他生理和心理症状，生活影响（即生活质量，残疾和一般功能）和卫生经济学/成本效用（例如医疗资源的使用和质量调整的生命年）。结论很少有经过充分验证的针对FND的结局指标。因此，目前，我们建议使用已知在FND或密切相关的人群中可靠，有效且反应迅速的结果指标来捕获关键的结果域。结果测量结果一致性的提高将有助于比较FND症状类型和治疗方式的治疗效果。

更新日期：2020-05-15

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>